Turn Therapeutics (TTRX) Income from Continuing Operations (2024 - 2026)
Turn Therapeutics' (TTRX) quarterly Income from Continuing Operations came in at 3146464.0 in Q1 2026, down 449.34% year-on-year from 900696.34 in Q1 2025, and down 7.5% quarter-over-quarter from 2927074.0 in Q4 2025.
Turn Therapeutics (TTRX) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Turn Therapeutics' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 3146464.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 449.34% year-over-year to 3146464.0 in Q1 2026; TTM through Mar 2026 was 14222169.0, a N/A change from a year earlier, with the FY2025 full-year figure at 13904726.0, down 146.3% from the prior year.
- Income from Continuing Operations eased to 3146464.0 in Q1 2026 per TTRX's latest filing, from 2927074.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 470237.0 in Q4 2024 and bottomed at 7575856.0 in Q3 2025.
- The 3-year median for Income from Continuing Operations is 1976403.0 (2024), against an average of 2619689.67.
- Across the five-year window, Income from Continuing Operations sank 638.58% in 2025 and tumbled 449.34% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 470237.0 in 2024, then sank by 522.47% to 2927074.0 in 2025, then fell by 7.5% to 3146464.0 in 2026.
- Per Business Quant, the three latest TTRX Income from Continuing Operations figures stand at 3146464.0 (Q1 2026), 2927074.0 (Q4 2025), and 7575856.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Turn Therapeutics | 253.20 Mn | 253.20 Mn | - | -3.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.15 Mn |
| Dec 31, 2025 | -2.93 Mn |
| Sep 30, 2025 | -7.58 Mn |
| Mar 31, 2025 | -572,775.00 |
| Dec 31, 2024 | -470,237.00 |
| Sep 30, 2024 | -1.03 Mn |